Kala Pharmaceuticals Inc

KALA BIO, Inc. is a biopharmaceutical company developing an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. It develops Researgency, an agentic AI research platform for private enterprise AI deployment. The platform is intended to use the KPI-012 clinical development dataset as a proof-of-concept validation environment, along with mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data. The company serves biotechnology and pharmaceutical companies. It was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. Incorporated in 2009, it is headquartered in Arlington, Massachusetts.